BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, announced today that its
Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief
Financial and Operating Officer, Philip Serlin, will be presenting at
the 17th Annual Rodman & Renshaw Global Investment Conference
at the St. Regis Hotel in New York City.
The BioLineRx presentation is scheduled to start at 10:00 a.m. EDT on
Wednesday, September 9, 2015. A live audio webcast of the presentation
will be available online at the investor page of the Company’s
website. An archive of the event will also be available for those
unable to listen live.
In addition, any investors attending the conference that wish to meet
with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact
Lily Khaykina at lk@rodm.com.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-8040, a cancer therapy platform,
which is in the midst of a Phase 2 study for relapsed/refractory acute
myeloid leukemia (AML), has recently initiated a Phase 2b study as an
AML consolidation treatment, and has successfully completed a Phase 1
study in stem cell mobilization; BL-7010 for celiac disease, which has
successfully completed a Phase 1/2 study; and BL-1040 for prevention of
pathological cardiac remodeling following a myocardial infarction, which
has been out-licensed to Bellerophon BCM (f/k/a Ikaria).
In December 2014, BioLineRx entered into a strategic collaboration
with Novartis for the co-development of selected Israeli-sourced novel
drug candidates. The companies intend to co-develop a number of
pre-clinical and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903005530/en/
Copyright Business Wire 2015